Announced details
Cell therapy for multiple myeloma, particularly relapsed or refractory patients who have received 3 or more prior lines of therapy
The treatment demonstrated tumor growth inhibition in a multiple myeloma xenograft mouse model. The quantitative effect is Not disclosed.
The company presented its research results and clinical trial design at IMS 2026.
An international conference held from 23 September 2026 to 26 September 2026 in Glasgow, Scotland, UK, attended by clinicians and researchers in the field of multiple myeloma.
The IND (Investigational New Drug application) is effective in the United States. The registration number and expiration date are Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
23rd International Myeloma Society Annual Meeting (IMS 2026), presentation number PA-058
| Item | Details |
|---|---|
| Names of Products / Services Covered | BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy) |
| Counterparty | 23rd International Myeloma Society Annual Meeting (IMS 2026) |
| Counterparty overview | An international conference held from 23 September 2026 to 26 September 2026 in Glasgow, Scotland, UK, attended by clinicians and researchers in the field of multiple myeloma. |
| Relationship with the Company | The company presented its research results and clinical trial design at IMS 2026. |
| Launch date | Presentation: noon on 23 September 2026 UK time (8:00 p.m. the same day Japan time). The Phase 1 clinical trial is planned, and the specific start date is Not disclosed. |
| Applicable area | Cell therapy for multiple myeloma, particularly relapsed or refractory patients who have received 3 or more prior lines of therapy |
| Registration number and expiry date | The IND (Investigational New Drug application) is effective in the United States. The registration number and expiration date are Not disclosed. |
| Quantitative Effects | The treatment demonstrated tumor growth inhibition in a multiple myeloma xenograft mouse model. The quantitative effect is Not disclosed. |
| Source | 23rd International Myeloma Society Annual Meeting (IMS 2026), presentation number PA-058 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report BP2202’s preclinical data and the Phase 1 clinical trial design at an international conference in the field of multiple myeloma.